As a single agent in the phase II MONO trial, zolbetuximab ORR was shown to be 9% in CLDN18.2-expressing tumours, and in the subgroup of moderate to strong CLDN18.2 expression (≥70% of tumour cells), the ORR was 14%. This evidence concerns the gene CLDN18 and neoplasm.